David Holland is a partner in Carpmaels & Ransford’s life sciences group. He frequently handles key pharma patents, from drafting through to post-grant opposition, for a wide range of small molecules and biologics. His familiarity with supplementary protection certificates (SPCs) allows him to provide his clients with comprehensive advice and judicious strategy, drawing upon his experience of patent and regulatory exclusivity. Recent highlights include prosecuting SPCs across Europe for Alofisel—one of the first cell therapies to be approved in Europe—as well as handling Europe-wide prosecution for products such as Hetlioz, Jakavi, Evarrest and Rebif.